|Result Analysis: Cipla Ltd.||Result Update Q3FY22|
|Particulars (In Rs. Cr.)||Q3FY22||Q2FY22||Q3FY21||QoQ %||YoY%|
|Revenue from Operations||5479||5520||5,169||-0.7%||6.0%|
|Raw Material Consumed||1,524.8||1,382.7||1,353.3||10.3%||12.7%|
|Purchase of finished Goods||716.6||875.5||604.5||-18.1%||18.5%|
|Employee Benefit Expenses||872.4||877.8||844.4||-0.6%||3.3%|
|Profit After Tax||759||712||753||6.6%||0.9%|
|EBITDA Margin||22.47%||22.21%||23.81%||25 bps||(135) bps|
|PAT Margin||13.63%||12.76%||14.32%||87 bps||(69) bps|
|Business Wise Performance (In Rs. Cr.)||Q3FY22||Q2FY22||Q3FY21||QoQ %||YoY%|
|India (Rx + Gx + CHL)||2518||2416||2,231||4.2%||12.9%|
Consolidated Revenue of Cipla for Q3FY22 registered strong growth of 6% YoY at Rs 5479 Crore beats the street estimates of Rs. 5295 Crore.
Net profit is up 1% YoY to Rs 759 crore. Sequentially Net Profit rose 6.6% led by higher other income and lower finance cost.
EBITDA margin rose sequentially by 25 bps to 22.47%. Margins down 135 bps YoY due to higher Cost of Good Sold and Other Expenses.
India Business grew by 13% YoY led by sustained momentum across core therapies and traction in flagship brands; modest contribution from covid portfolio.
US business Reported USD 150Mn revenue with robust momentum in core formulation business and strong traction in respiratory portfolio.
SAGA declined 4% YoY in US$ terms. South Africa private business grew 16% YoY in ZAR (Curreny of South Africa) terms and maintains market beating trajectory in secondary terms; tender business performed in-line with expectations.
Maintained its leadership in respiratory products with market share of 22.6% however market share is down from 23.1% in Q2FY22. In Urology market share is at 14.4%.
In Albuterol, Cipla’s TRx market share stood at 15.9% of the overall market as per IQVIA week ending 21st December 2021 increased from 14.6% for the overall market as per IQVIA week ending 8th October 2021.
In Arformoterol, Cipla’s TRx market stood at 26.8% of the overall market as per IQVIA week ending 21st December 2021 increased from 24% for the overall market as per IQVIA week ending 8th October 2021
New approval: Lanreotide injection 505 (b)(2); expands peptide portfolio
Products such as Omnigel, Cipladine, Cofsils, Prolyte ORS and Clocip delivered over 40% YoY growth in 9MFY22
Total Debt reduced from Rs. 1100 Crore in Q2FY22 to Rs. 880 Crore.
The board approved the transfer of the following undertakings as a going concern on a slump sale basis – 1) India based US business undertaking to Cipla BioTec and 2) Consumer business undertaking to Cipla Health
Management commentary: Umang Vohra MD and Global CEO, Cipla Ltd
I am pleased to see the strong launch and commercial momentum across our core markets during the quarter. Our portfolio execution in branded markets of India & South Africa and strong respiratory traction driving our US generic franchise to a multi-quarter high quarter were key drivers. The unlocking of our first 505(b)(2) peptide asset, lanreotide injection is an important step in strengthening our complex generics engine, inching up our US footprint. Our EBITDA margins for the quarter came in at 22.7% and given the YTD traction, we are well placed to close the year in-line with our guidance of 22%. We continue our efforts to improve patient access for therapies including covid products and ensuring adequate supply across all our markets.
Covid portfolio declined 10% YoY and 17% QoQ. Core business except Covid grew 16% YoY.
Expects significant momentum in US business from H2FY23 onwards on the back of possible approvals and launches of gRevlimid, gAdvair and gAbraxane besides momentum gains from Albuterol portfolio
Q3FY22 break-up: South Africa Private: US$60 million, South Africa Tender: US$23 million and Others: US$36 million
Global consumer business contributed ~8% to overall revenues YTD
R&D spend: Rs. 262 crore with priority projects on track, R&D to be around 7- 7.5% in future
Cipla has leadership positions across respiratory and urology segments, and have fifth rank in cardiology in India. Cipla Maintained its Robust momentum across key markets in Q3FY22 with strong traction in One-India and US business. Cipla’s strengthens its complex generics presence with the good response from Albuteral product and market share gain amid rise in demand for Albuterol products in the ongoing Covid-19 pandemic along with approval for first peptide asset, Lanreotide injection. Cipla files 2 important respiratory products filed in Europe. Other product launches and approvals are also continuing to accrue benefits. The consumer health business accounts for 5-6 percent of Cipla’s overall turnover which it aims to take beyond 12 per cent in the next five years. At the CMP of Rs. 902, Cipla is trading at PE multiple of 26.7x. Valuing the company at 21x FY23E EPS, we recommend buy on Cipla at CMP of Rs. 902 for the Target Price of Rs.1140.
Source: BSE, Bloomberg Quint, EW Research
Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, firstname.lastname@example.org
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing email@example.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail firstname.lastname@example.org.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL